Literature DB >> 20362204

Immune response induced by a linear DNA vector: influence of dose, formulation and route of injection.

Anne Endmann1, Michael Baden, Elena Weisermann, Kerstin Kapp, Matthias Schroff, Christiane Kleuss, Burghardt Wittig, Christiane Juhls.   

Abstract

Previously, minimalistic, immunogenetically defined gene expression (MIDGE) vectors were developed as effective and sophisticated carriers for DNA vaccination. Here we evaluate the influence of dose, formulation and delivery route on the immune response after vaccination with MIDGE-Th1 vectors encoding hepatitis B virus surface antigen (HBsAg). An HBsAg-specific IgG1 and IgG2a antibody response was induced in a dose-dependent manner, whereas the IgG2a/IgG1 ratio was independent of the injected DNA dose. Formulation of MIDGE-HBsAg-Th1 with the cationic pyridinium amphiphile SAINT-18 significantly increased antibody levels of IgG1 and IgG2a compared to the unformulated vector. In contrast, SAINT-18 had neither a significant effect on the IgG2a/IgG1 ratio nor on the type and strength of cellular immunity. Overall, the strongest immune response was generated after intradermal injection, followed by intramuscular and subcutaneous (s.c.) injection. The results show that the formulation of MIDGE-Th1 with SAINT-18 increased the efficacy of the MIDGE-Th1 DNA vaccine and is therefore a suitable approach to improve the efficacy of DNA vaccines also in large animals and humans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20362204     DOI: 10.1016/j.vaccine.2010.03.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response.

Authors:  Jessie Thalmensi; Elodie Pliquet; Christelle Liard; Marie Escande; Thomas Bestetti; Marion Julithe; Anna Kostrzak; Anne-Sophie Pailhes-Jimenez; Emanuèle Bourges; Maria Loustau; Julien Caumartin; Abderrahim Lachgar; Thierry Huet; Simon Wain-Hobson; Pierre Langlade-Demoyen
Journal:  Oncoimmunology       Date:  2015-11-05       Impact factor: 8.110

2.  Testing the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs.

Authors:  José E Aparicio-Burgos; Laucel Ochoa-García; José Antonio Zepeda-Escobar; Shivali Gupta; Monisha Dhiman; José Simón Martínez; Roberto Montes de Oca-Jiménez; Margarita Val Arreola; Alberto Barbabosa-Pliego; Juan C Vázquez-Chagoyán; Nisha Jain Garg
Journal:  PLoS Negl Trop Dis       Date:  2011-05-17

3.  Immune response of healthy horses to DNA constructs formulated with a cationic lipid transfection reagent.

Authors:  Christiane L Schnabel; P Steinig; M Koy; H-J Schuberth; C Juhls; D Oswald; B Wittig; S Willenbrock; H Murua Escobar; C Pfarrer; B Wagner; P Jaehnig; A Moritz; K Feige; J-M V Cavalleri
Journal:  BMC Vet Res       Date:  2015-06-23       Impact factor: 2.741

4.  Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.

Authors:  Kathrin Mählmann; Karsten Feige; Christiane Juhls; Anne Endmann; Hans-Joachim Schuberth; Detlef Oswald; Maren Hellige; Marcus Doherr; Jessika-M V Cavalleri
Journal:  BMC Vet Res       Date:  2015-06-11       Impact factor: 2.741

5.  Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.

Authors:  Kathrin Mählmann; Karsten Feige; Christiane Juhls; Anne Endmann; Hans-Joachim Schuberth; Detlef Oswald; Mareu Hellige; Marcus Doherr; Jessika-M V Cavalleri
Journal:  BMC Vet Res       Date:  2015-05-14       Impact factor: 2.741

6.  Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.

Authors:  Barbara Volz; Manuel Schmidt; Kerstin Heinrich; Kerstin Kapp; Matthias Schroff; Burghardt Wittig
Journal:  Mol Ther Oncolytics       Date:  2016-02-10       Impact factor: 7.200

7.  Advances in Non-Viral DNA Vectors for Gene Therapy.

Authors:  Cinnamon L Hardee; Lirio Milenka Arévalo-Soliz; Benjamin D Hornstein; Lynn Zechiedrich
Journal:  Genes (Basel)       Date:  2017-02-10       Impact factor: 4.096

8.  Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines.

Authors:  A A Walters; E Kinnear; R J Shattock; J U McDonald; L J Caproni; N Porter; J S Tregoning
Journal:  Gene Ther       Date:  2014-05-15       Impact factor: 5.250

9.  Cationic lipid-formulated DNA vaccine against hepatitis B virus: immunogenicity of MIDGE-Th1 vectors encoding small and large surface antigen in comparison to a licensed protein vaccine.

Authors:  Anne Endmann; Katharina Klünder; Kerstin Kapp; Oliver Riede; Detlef Oswald; Eduard G Talman; Matthias Schroff; Christiane Kleuss; Marcel H J Ruiters; Christiane Juhls
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

10.  Toll-Like Receptor 9 Activation Rescues Impaired Antibody Response in Needle-free Intradermal DNA Vaccination.

Authors:  Prabhu S Arunachalam; Ria Mishra; Krithika Badarinath; Deepak Selvam; Sravan K Payeli; Richard R Stout; Udaykumar Ranga
Journal:  Sci Rep       Date:  2016-09-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.